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Introduction: The aim of this study was to investigate the differential expression of markers related to metabolic,
mitochondrial and autophagy status in different molecular subtypes of breast cancer.
Methods: Using tissue microarray sections generated from 740 cases of breast cancer, we performed
immunohistochemical staining for Glut-1, CAIX, MCT4, ATP synthase, glutaminase, BNIP3, Beclin-1, LC3A, LC3B and
p62. Based on the immunohistochemical expression of estrogen receptor (ER), progesterone (PR), HER2, and Ki-67
labeling index, the cases were classified into luminal A, luminal B, HER2 and triple-negative breast cancer (TNBC).
We further classified metabolic phenotypes of tumors according to glycolytic status by assessing Glut-1 and CAIX
expression as follows: Warburg type: tumor (glycolysis type), stroma (nonglycolysis type); reverse Warburg type:
tumor (nonglycolysis type), stroma (glycolysis type); mixed type: tumor (glycolysis type), stroma (glycolysis type);
and null type: tumor (nonglycolysis type), stroma (nonglycolysis type).
Results: Expression of Glut-1, MCT4 and LC3A was highest in TNBC and lowest in luminal A type (P < 0.001).
Tumors were classified into 298 Warburg type (40.3%), 54 reverse Warburg type (7.3%), 62 mixed type (8.4%) and
326 null type (44.0%). The mixed type had a higher histologic grade, ER negativity, PR negativity and Ki-67 index,
whereas the null type showed lower histologic grade, ER positivity, PR positivity and Ki-67 index (P < 0.001). TNBC
constituted the major portion of Warburg and mixed types, and luminal A consisted mainly of reverse Warburg and
null types (P < 0.001).
Conclusion: Breast cancer is heterogeneous in its metabolic status, and therefore it can be classified into various
metabolic phenotypes. Specifically, the Warburg and mixed types had strong associations with TNBC, whereas
reverse the Warburg and null types had associations with the luminal type, suggesting a correlation between
metabolic phenotype and the biology of breast cancer.Introduction
The metabolism of malignant tumors is generally explained
by the Warburg effect theory, which describes the meta-
bolic shift from mitochondrial oxidative phosphorylation
(OXPHOS) to glycolysis in tumors [1]. Breast cancer is
known to be heterogeneous, and the interaction be-
tween tumor cells and adjacent stroma is expected to
have significant roles in tumor growth and progression.
This kind of complex interaction may also exist in the
metabolic processes of the tumor. Previous studies* Correspondence: kjs1976@yuhs.ac
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reproduction in any medium, provided the orsuggest a unique metabolic interaction between tumor
cells and the stroma of breast cancer, known as the reverse
Warburg effect theory [2-5]. According to this theory,
reactive oxygen species (ROS), such as nitric oxide
(NO), generated by tumor cells bring oxidative stress
to the stromal cells, leading to mitochondrial dysfunc-
tion, autophagy (mitophagy) and increased aerobic gly-
colysis through hypoxia-inducible factor 1α (HIF-1α)
and nuclear factor κB (NF-κB). Lactate generated by
stromal cell glycolysis enters tumor cells and promotesd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ation of ATP by OXPHOS in the mitochondria. Cancer-
associated fibroblasts (CAFs), stromal cells with loss of
caveolin-1 expression, have been implicated in this inter-
action in breast cancer because loss of caveolin-1 results
from increased proteolysis by autophagy [3,5-7]. In addition
to the reverse Warburg effect theory, it has been reported
that certain types of tumor cells generate ATP through
glycolysis as well as OXPHOS, which suggests various
features of tumor metabolism [8,9]. Proteins involved in
metabolism, mitochondrial function and autophagy may
be differentially expressed in both tumor and stromal cells
according to the aforementioned theories. These differences
are summarized in Table 1.
Because breast cancer is heterogeneous with respect to
clinical, histopathological and molecular features, several
subclassifications have been investigated to stratify tumors
with similar characteristics. Gene expression profiles have
enabled molecular classification of tumors into luminal A,
luminal B, HER2, normal breast-like and basal-like types
[10-12]. Studies have also revealed differences in histo-
logical and clinical manifestation between different molecu-
lar subtypes, such as therapeutic response and prognosis.
We hypothesized that the metabolic interaction between
tumor cells and stroma may differ according to the mo-
lecular subtypes of breast cancer. Because there are lim-
ited studies regarding this question, the aim of our present
study was designed to investigate the differential expression
of markers for metabolic, mitochondrial and autophagy
status in different molecular subtypes of breast cancer.
Methods
Patient selection
Patients diagnosed with invasive breast cancer treated by
surgical resection during the period from January 2002
to December 2006 were included in this study. Patients
who received preoperative neoadjuvant chemotherapy or
hormonal treatment were excluded. This study was ap-
proved by the Institutional Review Board (IRB) of Yonsei
University Severance Hospital. The IRB exempted the
informed consent from patients. A breast pathologist
(JSK) retrospectively reviewed the histology of all cases
using hematoxylin and eosin (H&E)-stained slides. The
histological grade was assessed using the NottinghamTable 1 Comparison of metabolism type, mitochondrial statu
theory and reverse Warburg effect theorya
Warburg effect theory
Cancer cell
Metabolism Glycolysis
Mitochondrial status Dysfunctional
Autophagy status Not included
aOXPHOS, oxidative phosphorylation.grading system [13]. Clinicopathologic parameters eval-
uated in each case included patient age at initial diagnosis,
lymph node metastasis, tumor recurrence, distant metasta-
sis and patient survival.
Tissue microarray
On H&E-stained slides of tumors, a representative area was
selected and the corresponding spot was marked on the
surface of the paraffin block. Using a biopsy needle, the se-
lected area was punched out and a 3-mm tissue core was
placed into a 6 × 5 recipient block. Tissue from the invasive
tumor was then extracted. More than two tissue cores were
extracted to minimize extraction bias. Each tissue core
was assigned a unique tissue microarray (TMA) location
number that was linked to a database containing other
clinicopathologic data.
Immunohistochemistry
The antibodies used for immunohistochemistry (IHC) in
this study are shown in Table 2. Formalin-fixed, paraffin-
embedded (FFPE) tissue sections from the TMA were
prepared for IHC. Briefly, 5-μm-thick sections were
obtained using a microtome, transferred into adhesive
slides and dried at 62°C for 30 min. After incubation
with primary antibodies, immunodetection was performed
with biotinylated anti-mouse immunoglobulin, followed by
peroxidase-labeled streptavidin using a labeled streptavidin
biotin kit with 3,3′-diaminobenzidine chromogen as
the substrate. The primary antibody incubation step was
omitted in the negative control. A positive control was in-
cluded for each experiment: glucose transporter 1 (Glut-1):
esophageal carcinoma; carbonic anhydrase IX (CAIX): renal
carcinoma; monocarboxylate transporter 4 (MCT4): BCL2/
adenovirus E1B 19-kDa interacting protein 3 (BNIP3),
kidney tissue; Beclin-1: breast tissue; microtubule-associated
protein 1 light chain 3α (LC3A): brain tissue; microtubule-
associated protein 1 light chain 3β (LC3B): brain tissue,
p62: spleen tissue; ATP synthase: heart tissue; and glu-
taminase: liver tissue. Slides were counterstained with
Harris hematoxylin.
Interpretation of immunohistochemical staining
All immunohistochemical markers were assessed by light
microscopy. Pathologic parameters such as ER, PR ands and autophagy status between the Warburg effect
Reverse Warburg effect theory
Cancer cell Stromal cell
OXPHOS Glycolysis
Functional Dysfunctional
Not activated Activated
Table 2 Source, clone and dilution of antibodies used in this studya
Antibody Clone Dilution Company
Molecular subtype-related
ER SP1 1:100 Thermo Scientific, Waltham, MA, USA
PR PgR 1:50 Dako Denmark AS, Glostrup, Denmark
HER2 Polyclonal 1:1,500 Dako Denmark AS, Glostrup, Denmark
Ki-67 MIB-1 1:150 Dako Denmark AS, Glostrup, Denmark
Glycolysis-related
Glut-1 SPM498 1:200 Abcam, Cambridge, UK
CAIX Polyclonal 1:100 Abcam, Cambridge, UK
MCT4 Polyclonal 1:100 Santa Cruz Biotechnology, Santa Cruz, CA, USA
Mitochondrial status-related
BNIP3 Ana40 1:100 Abcam, Cambridge, UK
Mitochondrial metabolism-related
ATP synthase 15H4C4 1:100 Abcam, Cambridge, UK
Glutaminase Polyclonal 1:100 Abcam, Cambridge, UK
Autophagy-related
Beclin-1 Polyclonal 1:100 Abcam, Cambridge, UK
LC3A EP1528Y 1:100 Abcam, Cambridge, UK
LC3B Polyclonal 1:100 Abcam, Cambridge, UK
p62 SQSTM1 1:100 Abcam, Cambridge, UK
aBNIP3, BCL2/adenovirus E1B 19-kDa interacting protein 3; CAIX, carbonic anhydrase IX; ER, estrogen receptor; Glut-1, glucose transporter 1; LC3A, microtubule-associated
protein 1 light chain 3α; LC3B, microtubule-associated protein 1 light chain 3β; MCT4, monocarboxylate transporter 4; PR, progesterone receptor.
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pathologic report. A cutoff value of 1% or more positively
stained nuclei was used to define ER and PR positivity
[14]. HER2 staining was analyzed according to the American
Society of Clinical Oncology (ASCO)/College of American
Pathologists (CAP) guidelines using the following cat-
egories: 0 = no immunostaining; 1+ = weak, incom-
plete membranous staining, less than 10% of tumor
cells; 2+ = complete membranous staining, either uniform
or weak in at least 10% of tumor cells; and 3+ = uniform
intense membranous staining in at least 30% of tumor cells
[15]. HER2 immunostaining was considered positive when
strong (3+) membranous staining was observed, whereas
cases with 0 to 1+ were regarded as negative. Cases show-
ing 2+ HER2 expression were evaluated for HER2 amplifi-
cation by fluorescence in situ hybridization (FISH).
Glut-1, CAIX, BNIP3, MCT4, Beclin-1, LC3A, LC3B
and p62 immunohistochemical staining was evaluated
on the basis of the proportion of stained cells and im-
munostaining intensity. The proportion of stained cells
was graded 0 (negative), 1 (less than 30% positive) or 2
(more than 30% positive). Immunostaining intensity was
graded as 0 (negative), 1 (weak), 2 (moderate) or 3 (strong).
The scores for the proportion of stained cells and staining
intensity were multiplied to provide a total score: negative
(0 or 1) or positive (2 through 6). Ki-67 labeling indices
(LIs) were scored by counting the number of positivelystained nuclei and expressed as a percentage of total
tumor cells.
Fluorescence in situ hybridization analysis
Before FISH analysis, invasive tumors were examined on
H&E-stained slides. FISH was subsequently performed
on the confirmed tumor. FISH was performed using the
PathVysion HER-2 DNA Probe Kit (Abbott Molecular,
Abbott Park, IL, USA) according to the manufacturer’s
instructions. HER2 gene copy number on the slides was
evaluated using an epifluorescence microscope (Olympus,
Tokyo, Japan). At least 60 tumor cell nuclei in three
separate regions were investigated for HER2 and chromo-
some 17 signals. HER2 gene amplification was determined
according to the ASCO/CAP guidelines [15]. An absolute
HER2 gene copy number lower than 4 or a HER2 gene/
chromosome 17 (chr17) copy number ratio (HER2/chr17
ratio) less than 1.8 was considered HER2-negative. An
absolute HER2 copy number between 4 and 6 or a HER2/
chr17 ratio between 1.8 and 2.2 was considered HER2-
equivocal. An absolute HER2 copy number greater than
6 or a HER2/chr17 ratio higher than 2.2 was considered
HER2-positive.
Tumor phenotype classification
In this study, we classified breast cancer phenotypes
according to the IHC results for ER, PR, HER2 and Ki-67
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A type: ER- and/or PR-positive, HER2-negative Ki-67 LI
less than 14%; luminal B type: (HER2-negative) ER- and/or
PR-positive, HER2-negative and Ki-67 LI greater than or
equal to 14% and (HER2-positive) ER- and/or PR-positive
and HER2 overexpressed and/or amplified; HER2 type: ER-
and PR-negative and HER2 overexpressed and/or amplified;
TNBC type: ER-, PR- and HER2-negative.
Classification of tumor metabolic subtypes
We also classified cases based on the results of immuno-
histochemical staining for metabolism-related proteins
as follows: glycolysis type: Glut-1- and/or CAIX-positive;
nonglycolysis type: Glut-1- and CAIX-negative; dysfunc-
tional mitochondrial type: BNIP3-positive [17,18]; func-
tional mitochondrial type: BNIP3-negative; activated
autophagy type: positive for two or more markers from
among Beclin-1, LC3A, LC3B and p62; and nonactivated
autophagy type: positive for less than two markers
from among Beclin-1, LC3A, LC3B and p62. We further
classified the metabolic phenotypes of breast cancer as
follows: Warburg type: tumor (glycolysis type), stroma
(nonglycolysis type); reverse Warburg type: tumor
(nonglycolysis type), stroma (glycolysis type); mixed type:
tumor (glycolysis type), stroma (glycolysis); and null type:
tumor (nonglycolysis type), stroma (non-glycolysis type).
Laser microdissection and protein extraction from
formalin-fixed, paraffin-embedded tissues
To acquire tumors and tumor stroma, laser microdissec-
tion was performed with hematoxylin-stained, uncovered
slides generated with FFPE blocks (LMD 6500; Leica,
Wetzlar, Germany). Five cases per molecular subtype of
breast cancer were microdissected. Protein extraction
from microdissected FFPE tissues was performed using
the Qproteome FFPE Tissue Kit (QIAGEN, Hilden,
Germany). Briefly, microdissected FFPE tissues were
deparaffinized in xylene and rehydrated in a graded
series of alcohol. Afterward, the samples were mixed
with FFPE extraction buffer EXB Plus (100 μl per sam-
ple; QIAGEN), incubated at 100°C for 20 min, at 80°C
for 2 h and then centrifuged for 15 min at 14,000 × g at
4°C. The protein concentrations in the supernatant were
determined using the Bradford assay (Bio-Rad Labora-
tories, Hercules, CA, USA).
Western blot analysis
Total protein (20 μg) from each sample was mixed with
Laemmli sample buffer and heated at 100°C for 5 min.
It was then loaded into individual wells, resolved by
8% SDS-PAGE and electroblotted onto nitrocellulose
membranes (GE Healthcare Life Sciences, Pittsburgh,
PA, USA). Membranes were blocked in 5% nonfat dry
milk in Tris-buffered saline with Tween 20 (TBS-T),then incubated with antibodies to Glut-1, CAIX, ATP
synthase, glutaminase, MCT-4, LC3A and p62 overnight
at 4°C. The membranes were washed with TBS-T and
then probed with peroxidase-conjugated goat anti-rabbit
immunoglobulin G (1:2,000; Santa Cruz Biotechnology,
Santa Cruz, CA, USA) for 1 h at room temperature.
Washing was repeated and the membranes were developed
with an enhanced chemiluminescence agent (Amersham/
GE Healthcare Life Sciences, Little Chalfont, UK). Band
densities were measured using TINA image software
(raytest, Straubenhardt, Germany).
Statistical analyses
Data were processed using SPSS for Windows version
12.0 software (SPSS Inc, Chicago, IL, USA). Student’s
t-test and Fisher’s exact test were used to examine any
differences in continuous and categorical variables, respect-
ively. Significance was assumed when P < 0.05. Kaplan-
Meier survival curves and logrank statistics were employed
to evaluate time to tumor recurrence and time to survival.
Multivariate regression analysis was performed using the
Cox proportional hazards model.
Results
Patients’ characteristics according to tumor phenotype
The clinicopathologic characteristics of 740 patients,
comprising 298 (40.3%) cases of luminal A, 166 (22.4%)
cases of luminal B, 69 (9.3%) cases of HER2 type and
207 (28%) cases of TNBC type, are summarized in Table 3.
TNBC type had the highest histologic grade, tumor
stage and Ki-67 LI (P < 0.001, P = 0.002 and P < 0.001,
respectively). In addition, HER2 and TNBC types had
higher incidences of tumor recurrence and patient death
than other types (P < 0.001).
Expression of metabolism-related proteins according to
tumor phenotype
The differential expression of metabolism-related proteins
according to breast cancer phenotype is summarized in
Table 4. Tumor expression of Glut-1, MCT4 and LC3A
was highest in TNBC and lowest in the luminal A type
(P < 0.001). Stromal expression of CAIX and MCT4
and tumor expression of cytoplasmic p62 was highest
in HER2 type and lowest in luminal A type (P = 0.032,
P < 0.001 and P < 0.001, respectively). Tumor expression
of CAIX and LC3B was highest in TNBC and lowest in
luminal B type (P = 0.008 and P = 0.013, respectively).
HER2 type showed the highest tumor and stromal ATP
synthase expression (P = 0.027 and P < 0.001, respectively)
and stromal glutaminase expression (P = 0.001), whereas
luminal A type showed the lowest expression of those
markers. Expression of stromal LC3A and tumor expres-
sion of nuclear p62 were highest in luminal A and lowest in
TNBC (P < 0.001).
Table 3 Clinicopathologic characteristics of patients according to breast cancer phenotypea
Parameters Total Luminal A Luminal B HER2 TNBC P-value
(N = 740) (%) (n = 298) (%) (n = 166) (%) (n = 69) (%) (n = 207) (%)
Age (years, mean ± SD) 49.7 ± 11.0 50.6 ± 10.5 48.5 ± 10.1 52.8 ± 9.8 48.4 ± 12.4 0.007
Histologic grade <0.001
I 118 (15.9) 90 (30.2) 18 (10.8) 1 (1.4) 9 (4.3)
II 373 (50.4) 180 (60.4) 90 (54.2) 35 (50.7) 68 (32.9)
III 249 (33.6) 28 (9.4) 58 (34.9) 33 (47.8) 130 (62.8)
Tumor stage 0.002
T1 358 (48.4) 166 (55.7) 86 (51.8) 31 (44.9) 75 (36.2)
T2 367 (49.6) 125 (41.9) 78 (47.0) 37 (53.6) 127 (61.4)
T3 15 (2.0) 7 (2.3) 2 (1.2) 1 (1.4) 5 (2.4)
Nodal stage 0.041
N0 436 (58.9) 168 (56.4) 91 (54.8) 42 (60.9) 135 (65.2)
N1 200 (27.0) 90 (30.2) 43 (25.9) 13 (18.8) 54 (26.1)
N2 66 (8.9) 27 (9.1) 17 (18.5) 10 (14.5) 12 (5.8)
N3 38 (5.1) 13 (4.4) 15 (9.0) 4 (5.8) 6 (2.9)
Estrogen receptor status <0.001
Negative 286 (38.6) 5 (1.7) 5 (3.0) 69 (100.0) 207 (100.0)
Positive 454 (61.4) 293 (98.3) 161 (97.0) 0 (0.0) 0 (0.0)
Progesterone receptor status <0.001
Negative 371 (50.1) 50 (16.8) 46 (27.7) 69 (100.0) 207 (100.0)
Positive 369 (49.9) 248 (83.2) 120 (72.3) 0 (0.0) 0 (0.0)
HER2 status <0.001
0 290 (39.2) 108 (36.2) 23 (13.9) 0 (0.0) 159 (76.8)
1+ 186 (25.1) 118 (39.6) 33 (20.0) 0 (0.0) 35 (16.9)
2+ 142 (19.2) 72 (24.2) 41 (24.7) 16 (23.2) 13 (6.3)
3+ 122 (16.5) 0 (0.0) 69 (41.6) 53 (76.8) 0 (0.0)
Ki-67 LI (%, mean ± SD) 18.1 ± 19.2 4.7 ± 3.7 19.7 ± 12.7 19.5 ± 12.5 35.6 ± 23.7 <0.001
Tumor recurrence 69 (9.3) 15 (5.0) 12 (7.2) 11 (15.9) 31 (15.0) <0.001
Patient’s death 67 (9.1) 14 (4.7) 11 (6.6) 12 (17.4) 30 (14.5) <0.001
Duration of clinical follow-up (months, mean ± SD) 70.2 ± 31.7 72.7 ± 30.0 70.3 ± 30.3 67.1 ± 35.8 67.8 ± 33.8 0.291
aLI, labeling index; TNBC triple-negative breast cancer.
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clinicopathologic factors
The correlation between expression of metabolism-related
proteins and clinicopathologic parameters is summarized
in Table 5. Tumor expression of Glut-1 was associated
with higher histologic grade (P < 0.001), ER negativity
(P < 0.001), higher T stage (P < 0.001) and higher Ki-
67 LI (P < 0.001), whereas CAIX was associated with
higher Ki-67 LI (P < 0.001). Stromal ATP synthase expres-
sion was associated with HER2 positivity (P < 0.001),
and stromal glutaminase expression was associated with
higher KI-67 LI (P = 0.021). Tumor expression of MCT4
was associated with higher histologic grade (P < 0.001),
ER negativity (P < 0.001), PR negativity (P < 0.001), higher
T stage (P < 0.001) and higher Ki-67 LI (P < 0.001).Stromal expression of MCT4 was associated with higher
histologic grade (P < 0.001), ER negativity (P < 0.001),
PR negativity (P < 0.001), HER2 positivity (P < 0.001)
and higher Ki-67 LI (P < 0.001). Tumor expression
of LC3A was associated with higher histologic grade
(P < 0.001), ER negativity (P < 0.001), PR negativity
(P < 0.001), HER2 negativity (P < 0.001) and higher Ki-67
LI (P < 0.001). In contrast, stromal expression of LC3A
was associated with ER positivity (P < 0.001), PR posi-
tivity (P < 0.001) and lower Ki-67 LI (P = 0.032). Tumor
expression of cytoplasmic p62 was associated with
HER2 positivity (P < 0.001), whereas nuclear p62 was
associated with lower histologic grade (P < 0.001), ER
positivity (P < 0.001), PR positivity (P < 0.001) and lower
Ki-67 LI (P < 0.001).
Table 4 Expression of metabolism-related proteins according to breast cancer phenotypea
Parameters Total Luminal A Luminal B HER2 TNBC P-value
(N = 740 ) (%) (n = 298 ) (%) (n = 166) (%) (n = 69) (%) (n = 207) (%)
Glut-1 in tumor <0.001
Negative 504 (68.1) 260 (87.2) 124 (74.7) 47 (68.1) 73 (35.3)
Positive 236 (31.9) 38 (12.8) 42 (25.3) 22 (31.9) 134 (64.7)
Glut-1 in stroma 0.103
Negative 724 (97.8) 296 (99.3) 162 (97.6) 66 (95.7) 200 (96.6)
Positive 16 (2.2) 2 (0.7) 4 (2.4) 3 (4.3) 7 (3.4)
CAIX in tumor 0.008
Negative 520 (70.3) 217 (72.8) 127 (76.5) 49 (71.0) 127 (61.3)
Positive 220 (29.7) 81 (27.2) 39 (23.5) 20 (29.0) 80 (38.6)
CAIX in stroma 0.032
Negative 627 (84.7) 264 (88.6) 137 (82.5) 52 (75.4) 174 (84.1)
Positive 113 (15.3) 34 (11.4) 29 (17.5) 17 (24.6) 33 (15.9)
ATP synthase in tumor 0.027
Negative 30 (4.1) 20 (6.7) 4 (2.4) 1 (1.4) 5 (2.4)
Positive 710 (95.9) 278 (93.3) 162 (97.6) 68 (98.6) 202 (97.6)
ATP synthase in stroma <0.001
Negative 570 (77.0) 256 (85.9) 112 (67.5) 38 (55.1) 164 (79.2)
Positive 170 (23.0) 42 (14.1) 54 (32.5) 31 (44.9) 43 (20.8)
Glutaminase in tumor 0.164
Negative 219 (29.6) 85 (28.5) 60 (36.1) 21 (30.4) 53 (25.6)
Positive 521 (70.4) 213 (71.5) 106 (63.9) 48 (69.6) 154 (74.4)
Glutaminase in stroma 0.001
Negative 495 (66.9) 223 (74.8) 105 (63.3) 39 (56.5) 128 (61.8)
Positive 245 (33.1) 75 (25.2) 61 (36.7) 30 (43.5) 79 (38.2)
BNIP3 in tumor 0.262
Negative 504 (68.1) 206 (69.1) 112 (67.5) 40 (58.0) 146 (70.5)
Positive 236 (31.9) 92 (30.9) 54 (32.5) 29 (42.0) 61 (29.5)
BNIP3 in stroma 0.262
Negative 700 (94.6) 281 (94.3) 159 (95.8) 62 (89.9) 198 (95.7)
Positive 40 (5.4) 17 (5.7) 7 (4.2) 7 (10.1) 9 (4.3)
MCT4 in tumor <0.001
Negative 540 (73.0) 253 (84.9) 118 (71.1) 49 (71.0) 120 (58.0)
Positive 200 (27.0) 45 (15.1) 48 (28.9) 20 (29.0) 87 (42.0)
MCT4 in stroma <0.001
Negative 418 (56.5) 222 (74.5) 81 (48.8) 23 (33.3) 92 (44.4)
Positive 322 (43.5) 76 (25.5) 85 (51.2) 46 (66.7) 115 (55.6)
Cytoplasmic Beclin-1 0.137
Negative 406 (54.9) 169 (56.7) 99 (59.6) 31 (44.9) 107 (51.7)
Positive 334 (45.1) 129 (43.3) 67 (33.7) 38 (55.1) 100 (48.3)
Nuclear Beclin-1 <0.001
Negative 666 (90.0) 262 (87.9) 152 (91.6) 55 (79.7) 197 (95.2)
Positive 74 (10.0) 36 (12.1) 14 (8.4) 14 (20.3) 10 (4.8)
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Table 4 Expression of metabolism-related proteins according to breast cancer phenotypea (Continued)
LC3A in tumor <0.001
Negative 669 (90.4) 294 (98.7) 158 (95.2) 68 (98.6) 149 (72.0)
Positive 71 (9.6) 4 (1.3) 8 (4.8) 1 (1.4) 58 (28.0)
LC3A in stroma <0.001
Negative 687 (92.8) 267 (89.6) 151 (91.0) 62 (89.9) 207 (100.0)
Positive 53 (7.2) 31 (10.4) 15 (9.0) 7 (10.1) 0 (0.0)
LC3B in tumor 0.013
Negative 475 (64.2) 186 (62.4) 124 (74.7) 42 (60.9) 123 (59.4)
Positive 265 (35.8) 112 (37.6) 42 (25.3) 27 (39.1) 84 (40.6)
LC3B in stroma 0.645
Negative 688 (93.0) 277 (93.0) 151 (91.0) 65 (94.2) 195 (94.2)
Positive 52 (7.0) 21 (7.0) 15 (9.0) 4 (5.8) 12 (5.8)
Cytoplasmic p62 in tumor <0.001
Negative 274 (37.0) 131 (44.0) 51 (30.7) 15 (21.7) 77 (37.2)
Positive 466 (63.0) 167 (56.0) 115 (69.3) 54 (78.3) 130 (62.8)
Nuclear p62 in tumor <0.001
Negative 532 (71.9) 180 (60.4) 131 (78.9) 44 (63.8) 177 (85.5)
Positive 208 (28.1) 118 (39.6) 35 (21.1) 25 (36.2) 30 (14.5)
Nuclear p62 in stroma 0.876
Negative 512 (69.2) 206 (69.1) 115 (69.3) 45 (65.2) 146 (70.5)
Positive 228 (30.8) 92 (30.9) 51 (30.7) 24 (34.8) 61 (29.5)
aBNIP3, BCL2/adenovirus E1B 19-kDa interacting protein 3; CAIX, carbonic anhydrase IX; Glut-1, glucose transporter 1; LC3A, microtubule-associated protein 1 light
chain 3α; LC3B, microtubule-associated protein 1 light chain 3β; MCT4, monocarboxylate transporter 4; TNBC, triple-negative breast cancer.
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clinicopathologic factors
The correlation between the metabolic phenotype of breast
cancer and clinicopathologic parameters is summarized
in Table 6 and Figure 1. The metabolic phenotype was
the Warburg type (n = 298, 40.3%), the null type (n =
326, 44.0%), the mixed type (n = 62, 8.4%) and the reverse
Warburg type (n = 54, 7.3%). Histologic grade was highest
in the mixed type and lowest in the null type (P < 0.001).
The mixed type had the highest percentage of ER and PR
negativity, and the null type had the highest percentage of
ER and PR positivity (P < 0.001). The Warburg type had
the highest percentage of negative HER2 status (P =
0.006). The Warburg and mixed types comprised the
highest percentage of TNBC, and the reverse Warburg
and null types comprised the highest percentage of lu-
minal A types (P < 0.001). Stromal expression of ATP
synthase and glutaminase was high in the reverse
Warburg and mixed types and low in the Warburg and
null types (P < 0.001). For the status of tumor auto-
phagy, the mixed type had the highest percentage of
activated tumor autophagy and the null type had the
highest percentage of nonactivated tumor autophagy
(P < 0.001). For the status of stromal autophagy, the reverseWarburg and mixed types had a higher percentage of
activation than other types (P < 0.001). Tumor expression
of MCT4 was highest in the Warburg type and lowest in
the null type (P < 0.001), whereas stromal expression of
MCT4 was highest in the mixed type and lowest in the
null type (P < 0.001). Ki-67 LI was highest in the mixed
type and lowest in the null type (P < 0.001).
Impact of metabolism-related proteins on patient prognosis
The results of univariate analysis on the correlation
between metabolism-related proteins and the clinico-
pathologic parameters of patients are summarized in
Table 7. Shorter disease-free survival (DFS) was associated
with Glut-1 positivity (P = 0.010), BNIP3 negativity, tumor
phenotype (HER2 and TNBC; P < 0.001) and tumor
metabolic type (reverse Warburg type; P = 0.037) (Figure 2).
Shorter overall survival (OS) was associated with Glut-1
positivity (P = 0.023), tumor phenotype (HER2 and
TNBC; P < 0.001) and tumor metabolic type (mixed type;
P = 0.045) (Figure 2). Prognostic factors evaluated by
multivariate Cox analysis included histologic grade, T stage,
N stage, ER status, PR status, HER2 status, tumor pheno-
type, tumor metabolic phenotype and tumor expression of
Glut-1. The results showed that the independent factors
Table 5 Correlations between the expression of metabolism-related proteins and clinicopathologic parametersa
Parameters Glut-1 in tumor Glut-1 in stroma CAIX in tumor CAIX in stroma
Negative Positive Negative Positive Negative Positive Negative Positive
(n = 504)
(%)
(n = 236)
(%)
P-value (n = 724)
(%)
(n = 16)
(%)
P-value (n = 520)
(%)
(n = 220)
(%)
P-value (n = 627)
(%)
(n = 113)
(%)
P-value
Age (years,
mean ± SD)
50.5 ± 10.7 48.1 ± 11.4 0.126 49.7 ± 110.0 49.3 ± 9.0 18.14 49.7 ± 11.0 49.8 ± 11.0 19.67 49.3 ± 11.1 51.7 ± 10.3 0.840
Histologic grade <0.001 8.946 0.441 0.483
I/II 392 (71.8) 99 (41.9) 482 (67.3) 9 (56.3) 359 (69.0) 132 (60.0) 427 (68.1) 64 (56.6)
III 112 (22.2) 137 (58.1) 242 (33.4) 7 (43.7) 161 (31.0) 88 (40.0) 200 (31.9) 49 (43.4)
ER <0.001 0.378 0.042 1.113
Negative 128 (25.4) 158 (66.9) 275 (38.0) 11 (68.8) 182 (35.0) 104 (47.3) 233 (37.2) 53 (46.9)
Positive 376 (74.6) 78 (33.1) 449 (62.0) 5 (31.2) 338 (65.0) 116 (52.7) 394 (62.8) 60 (53.1)
PR <0.001 4.305 10.92 8.715
Negative 190 (37.7) 182 (77.1) 361 (49.9) 11 (68.8) 257 (49.4) 115 (52.3) 311 (49.6) 61 (54.0)
Positive 314 (62.3) 54 (22.9) 363 (50.1) 5 (31.2) 263 (50.6) 105 (47.7) 316 (50.4) 52 (46.0)
HER2 0.714 6.741 0.294 1.260
Negative 386 (76.6) 197 (83.5) 572 (79.0) 11 (68.8) 397 (76.3) 186 (84.5) 502 (80.1) 81 (71.7)
Positive 118 (23.4) 39 (16.5) 152 (21.0) 5 (31.2) 123 (23.7) 34 (15.5) 125 (19.9) 32 (28.3)
Tumor stage <0.001 18.81 19.65 3.192
T1 270 (53.6) 88 (37.3) 350 (48.3) 8 (50.0) 251 (48.3) 107 (48.6) 296 (47.2) 62 (54.9)
T2/T3 234 (46.4) 148 (62.7) 374 (51.7) 8 (50.0) 269 (51.7) 113 (51.4) 331 (52.8) 51 (45.1)
Nodal stage 1.932 16.12 15.62 15.87
N0 286 (56.7) 150 (63.6) 426 (58.8) 10 (62.5) 304 (58.5) 132 (60.0) 371 (59.2) 65 (57.5)
N1/N2/N3 218 (43.3) 86 (36.4) 298 (41.2) 6 (37.5) 216 (41.5) 88 (40.0) 256 (40.8) 48 (42.5)
Ki-67 LI (%,
mean ± SD)
12.7 ± 14.9 29.6 ± 22.1 <0.001 18.0 ± 19.3 22.5 ± 14.7 7.497 16.1 ± 17.5 22.7 ± 22.1 <0.001 17.8 ± 19.7 19.5 ± 16.7 8.505
Tumor recurrence 0.210 8.106 18.62 17.85
Absent 467 (92.7) 204 (86.4) 655 (90.5) 16 (100.0) 471 (90.6) 200 (90.9) 568 (90.6) 103 (91.2)
Present 37 (7.3) 32 (13.6) 69 (9.5) 0 (0.0) 49 (9.4) 20 (9.1) 59 (9.4) 10 (9.8)
Death 0.420 8.085 11.76 15.22
Survival 467 (92.7) 206 (87.3) 657 (90.7) 16 (100.0) 475 (91.3) 198 (90.0) 571 (91.1) 102 (90.3)
Death 37 (7.3) 30 (12.7) 67 (9.3) 0 (0.0) 45 (8.7) 22 (10.0) 56 (8.9) 11 (9.7)
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Table 5 Correlations between the expression of metabolism-related proteins and clinicopathologic parametersa (Continued)
Parameters ATP synthase in tumor ATP synthase in stroma Glutaminase in tumor Glutaminase in stroma
Negative Positive Negative Positive Negative Positive Negative Positive
(n = 30)
(%)
(n = 710)
(%)
P-value (n = 570)
(%)
(n = 170)
(%)
P-value (n = 219)
(%)
(n = 521)
(%)
P-value (n = 495)
(%)
(n = 245)
(%)
P-value
Age (years,
mean ± SD)
46.7 ± 9.3 49.9 ± 11.0 2.478 49.5 ± 11.2 50.4 ± 10.0 7.539 49.2 ± 11.6 49.9 ± 10.7 11.90 49.5 ± 11.1 50.4 ± 10.7 5.124
Histologic grade 11.63 0.252 16.77 0.168
I/II 22 (733) 469 (66.1) 392 (68.8) 99 (58.2) 147 (67.1) 344 (66.0) 345 (69.7) 146 (59.6)
III 8 (26.7) 241 (33.9) 178 (31.2) 71 (41.8) 72 (32.9) 177 (34.0) 150 (30.3) 99 (40.4)
ER 1.827 1.533 4.536 0.126
Negative 7 (23.3) 279 (39.3) 210 (36.8) 76 (44.7) 77 (35.2) 209 (40.1) 174 (35.2) 112 (45.7)
Positive 23 (76.7) 431 (60.7) 360 (63.2) 94 (55.3) 142 (64.8) 312 (59.9) 321 (64.8) 133 (54.3)
PR 0.189 0.609 4.158 0.735
Negative 8 (26.7) 364 (51.3) 274 (48.1) 98 (57.6) 102 (46.6) 270 (51.8) 235 (47.5) 137 (55.9)
Positive 22 (73.3) 346 (48.7) 296 (51.9) 72 (42.4) 117 (53.4) 251 (48.2) 260 (52.5) 108 (44.1)
HER2 3.570 <0.001 13.08 3.822
Negative 27 (90.0) 556 (78.3) 472 (82.8) 111 (65.3) 170 (77.6) 413 (79.3) 397 (80.2) 186 (75.9)
Positive 3 (10.0) 154 (21.7) 98 (17.2) 59 (34.7) 49 (22.4) 108 (20.7) 98 (19.8) 59 (24.1)
Tumor stage 7.539 21.00 7.875 18.39
T1 12 (40.0) 346 (48.7) 276 (48.4) 82 (48.2) 100 (45.7) 258 (49.5) 238 (48.1) 120 (49.0)
T2/T3 18 (60.0) 364 (51.3) 294 (51.6) 88 (51.8) 119 (54.3) 263 (50.5) 257 (51.9) 125 (51.0)
Nodal stage 7.266 6.027 7.728 8.967
N0 15 (50.0) 421 (59.3) 342 (60.0) 94 (55.3) 135 (61.6) 301 (57.8) 297 (60.0) 139 (56.7)
N1/N2/N3 15 (50.0) 289 (40.7) 228 (40.0) 76 (44.7) 84 (38.4) 220 (42.2) 198 (40.0) 106 (43.3)
Ki-67 LI (%,
mean ± SD)
9.8 ± 11.7 18.4 ± 19.4 0.336 17.3 ± 19.7 20.8 ± 17.5 0.798 18.6 ± 20.0 17.8 ± 18.9 13.50 15.6 ± 17.2 22.9 ± 22.0 0.021
Tumor recurrence 10.79 21.00 7.014 10.56
Absent 26 (86.7) 645 (90.8) 517 (90.7) 154 (90.6) 195 (89.0) 476 (91.4) 446 (90.1) 225 (91.8)
Present 4 (13.3) 65 (9.2) 53 (9.3) 16 (9.4) 24 (11.0) 45 (8.6) 49 (9.9) 20 (8.2)
Death 15.68 13.60 3.381 8.757
Survival 27 (90.0) 646 (91.0) 520 (91.2) 153 (90.0) 194 (88.6) 479 (91.9) 447 (90.3) 226 (92.2)
Death 3 (10.0) 64 (9.0) 50 (8.8) 17 (10.0) 25 (11.4) 42 (8.1) 48 (9.7) 19 (7.8)
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Table 5 Correlations between the expression of metabolism-related proteins and clinicopathologic parametersa (Continued)
Parameters BNIP3 in tumor BNIP3 in stroma MCT4 in tumor MCT4 in stroma
Negative Positive Negative Positive Negative Positive Negative Positive
(n =504)
(%)
(n = 236)
(%)
P-value (n = 700)
(%)
(n = 40)
(%)
P-value (n = 540)
(%)
(n = 200)
(%)
P-value (n = 418)
(%)
(n = 322)
(%)
P-value
Age
(years, mean ± SD)
48.9 ± 10.9 51.6 ± 11.0 0.042 49.5 ± 10.8 53.2 ± 12.7 0.882 49.8 ± 11.1 49.6 ± 10.6 17.91 49.6 ± 11.0 49.5 ± 10.9 14.80
Histologic grade 5.859 15.37 <0.001 <0.001
I/II 341 (67.7) 150 (63.6) 463 (66.1) 28 (70.0) 386 (71.5) 105 (52.5) 314 (75.1) 177 (55.0)
III 163 (32.3) 86 (36.4) 237 (33.9) 12 (30.0) 154 (28.5) 95 (47.5) 104 (24.9) 145 (45.0)
ER 14.40 12.99 <0.001 <0.001
Negative 192 (38.1) 94 (39.8) 269 (38.4) 17 (42.5) 174 (32.2) 112 (56.0) 123 (29.4) 163 (50.6)
Positive 312 (61.9) 142 (60.2) 431 (61.6) 23 (57.5) 366 (67.8) 88 (44.0) 295 (70.6) 159 (49.4)
PR 17.07 8.757 <0.001 <0.001
Negative 255 (50.6) 117 (49.6) 349 (49.9) 23 (57.5) 232 (43.0) 140 (70.0) 179 (42.8) 193 (60.0)
Positive 249 (49.4) 119 (50.4) 351 (50.1) 17 (42.5) 308 (57.0) 60 (30.0) 239 (57.2) 129 (40.0)
HER2 4.410 6.762 11.42 <0.001
Negative 404 (80.2) 179 (75.8) 554 (79.1) 29 (72.5) 422 (78.1) 161 (80.5) 356 (85.2) 227 (70.5)
Positive 100 (19.8) 57 (24.2) 146 (20.9) 11 (27.5) 118 (21.9) 39 (19.5) 62 (14.8) 95 (29.5)
Tumor stage 1.449 15.66 <0.001 7.854
T1 232 (46.0) 126 (53.4) 340 (48.6) 18 (45.0) 283 (52.4) 75 (37.5) 196 (46.9) 162 (50.3)
T2/T3 272 (54.0) 110 (46.6) 360 (51.4) 22 (55.0) 257 (47.6) 125 (62.5) 222 (53.1) 160 (49.7)
Nodal stage 6.237 0.630 18.20 7.686
N0 290 (57.5) 146 (61.9) 419 (59.9) 17 (42.5) 317 (58.7) 119 (59.5) 240 (57.4) 196 (60.9)
N1/N2/N3 214 (42.5) 90 (38.1) 281 (40.1) 23 (57.5) 223 (41.3) 81 (40.5) 178 (42.6) 126 (39.1)
Ki-67 LI (%,
mean ± SD)
18.9 ± 20.9 16.2 ± 15.0 1.680 18.3 ± 19.5 14.6 ± 13.7 5.208 15.3 ± 17.8 25.6 ± 21.0 <0.001 13.2 ± 16.5 24.3 ± 20.7 <0.001
Tumor recurrence 0.021 3.444 14.11 11.00
Absent 445 (88.3) 226 (95.8) 632 (90.3) 39 (97.5) 491 (90.9) 180 (90.0) 376 (90.0) 295 (91.6)
Present 59 (11.7) 10 (4.2) 68 (9.7) 1 (2.5) 49 (9.1) 20 (10.0) 42 (10.0) 27 (8.4)
Death 5.712 15.22 11.90 2.562
Survival 454 (90.1) 219 (92.8) 636 (90.9) 37 (92.5) 493 (91.3) 180 (90.0) 374 (89.5) 299 (92.9)
Death 50 (9.9) 17 (7.2) 64 (9.1) 3 (7.5) 47 (8.7) 20 (10.0) 44 (10.5) 23 (7.1)
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Table 5 Correlations between the expression of metabolism-related proteins and clinicopathologic parametersa (Continued)
Parameters Cytoplasmic Beclin-1 Nuclear Beclin-1 LC3A in tumor LC3A in stroma
Negative Positive Negative Positive Negative Positive Negative Positive
(n = 406)
(%)
(n = 334)
(%)
P-value (n = 666)
(%)
(n = 74)
(%)
P-value (n = 669)
(%)
(n = 71)
(%)
P-value (n = 687)
(%)
(n = 53)
(%)
P-value
Age (years,
mean ± SD)
48.6 ± 10.5 51.1 ± 11.4 0.042 49.6 ± 11.1 50.8 ± 9.9 8.316 50.2 ± 11.0 45.6 ± 9.8 0.021 49.7 ± 11.0 49.6 ± 9.2 19.65
Histologic grade 14.61 <0.001 <0.001 1.029
I/II 272 (67.0) 219 (65.6) 427 (64.1) 64 (86.5) 470 (70.3) 21 (29.6) 449 (65.4) 42 (79.2)
III 134 (33.0) 115 (34.4) 239 (35.9) 10 (13.5) 199 (29.7) 50 (70.4) 238 (34.6) 11 (20.8)
ER 6.090 8.022 <0.001 <0.001
Negative 143 (35.2) 143 (42.8) 261 (39.2) 25 (33.8) 226 (33.8) 60 (84.5) 278 (40.5) 8 (15.1)
Positive 263 (64.8) 191 (57.2) 405 (60.8) 49 (66.2) 443 (66.2) 11 (15.5) 409 (59.5) 45 (84.9)
PR 19.76 1.827 <0.001 <0.001
Negative 205 (50.5) 167 (50.0) 342 (51.4) 30 (40.5) 309 (46.2) 63 (88.7) 360 (52.4) 12 (22.6)
Positive 201 (49.5) 167 (50.0) 324 (48.6) 44 (59.5) 360 (53.8) 8 (11.3) 327 (47.6) 41 (77.4)
HER2 12.36 0.336 <0.001 8.022
Negative 323 (79.6) 260 (77.8) 533 (80.0) 50 (67.6) 515 (76.9) 68 (95.8) 544 (79.2) 39 (73.6)
Positive 83 (20.4) 74 (22.2) 133 (20.0) 24 (32.4) 154 (23.1) 3 (4.2) 143 (20.8) 14 (26.4)
Tumor stage 0.042 6.888 16.86 0.210
T1 175 (43.1) 183 (54.8) 318 (47.7) 40 (54.1) 325 (48.6) 33 (46.5) 323 (47.0) 35 (66.0)
T2/T3 231 (56.9) 151 (45.2) 348 (52.3) 34 (45.9) 344 (51.4) 38 (53.5) 364 (53.0) 18 (34.0)
Nodal stage 13.71 3.612 6.552 16.23
N0 236 (58.1) 200 (59.9) 398 (59.8) 38 (51.4) 390 (58.3) 46 (64.8) 406 (59.1) 30 (56.6)
N1/N2/N3 170 (41.9) 134 (40.1) 268 (40.2) 36 (48.6) 279 (41.7) 25 (35.2) 281 (40.9) 23 (43.4)
Ki-67 LI (%,
mean ± SD)
17.8 ± 19.4 18.3 ± 19.1 0.042 19.0 ± 19.8 9.5 ± 10.0 <0.001 15.7 ± 17.2 39.6 ± 23.1 <0.001 18.7 ± 19.7 10.4 ± 9.6 0.032
Tumor recurrence 0.882 2.877 4.053 16.98
Absent 360 (88.7) 311 (93.1) 600 (90.1) 71 (95.9) 610 (91.2) 61 (85.9) 622 (90.5) 49 (92.5)
Present 46 (11.3) 23 (6.9) 66 (9.9) 3 (4.1) 59 (8.8) 10 (14.1) 65 (9.5) 4 (7.5)
Death 16.75 0.189 10.75 9.765
Survival 368 (90.6) 305 (91.3) 600 (90.1) 73 (98.6) 610 (91.2) 63 (88.7) 623 (90.7) 50 (94.3)
Death 38 (9.4) 29 (8.7) 66 (9.9) 1 (1.4) 59 (8.8) 8 (11.3) 64 (9.3) 3 (5.7)
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Table 5 Correlations between the expression of metabolism-related proteins and clinicopathologic parametersa (Continued)
Parameters LC3B in tumor LC3B in stroma Cytoplasmic p62 in tumor Nuclear p62 in tumor Nuclear p62 in stroma
Negative Positive Negative Positive Negative Positive Negative Positive Negative Positive
(n = 475)
(%)
(n = 265)
(%)
P-value (n = 688)
(%)
(n = 52)
(%)
P-value (n = 274)
(%)
(n = 466)
(%)
P-value (n = 532)
(%)
(n = 208)
(%)
P-value (n = 512)
(%)
(n = 228)
(%)
P-value
Age 49.4 ± 10.4 50.4 ± 12.0 4.599 49.6 ± 11.0 51.1 ± 10.6 15.77 49.4 ± 10.3 49.9 ± 11.4 10.35 49.4 ± 10.9 50.6 ± 11.2 3.717 49.5 ± 11.2 50.3 ± 10.4 6.741
(years, mean ± SD)
Histologic grade 3.528 9.450 0.210 <0.001 18.18
I/II 324 (68.2) 167 (63.0) 459 (66.7) 32 (61.5) 198 (72.3) 293 (62.9) 322 (60.5) 169 (81.3) 341 (66.6) 150 (65.8)
III 151 (31.8) 98 (37.0) 229 (33.3) 20 (38.5) 76 (27.7) 173 (37.1) 210 (39.5) 39 (18.8) 171 (33.4) 78 (34.2)
ER 6.279 7.980 2.877 <0.001 14.34
Negative 173 (36.4) 113 (42.6) 269 (39.1) 17 (32.7) 96 (35.0) 190 (40.8) 227 (42.7) 59 (28.4) 195 (38.1) 91 (39.9)
Positive 302 (63.6) 152 (57.4) 419 (60.9) 35 (67.3) 178 (65.0) 276 (59.2) 305 (57.3) 149 (71.6) 317 (61.9) 137 (60.1)
PR 10.29 5.292 0.105 <0.001 17.05
Negative 234 (49.3) 138 (52.1) 350 (50.9) 22 (42.3) 119 (43.4) 253 (54.3) 293 (55.1) 79 (38.0) 259 (50.6) 113 (49.6)
Positive 241 (50.7) 127 (47.9) 338 (49.1) 30 (57.7) 155 (56.6) 213 (45.7) 239 (44.9) 129 (62.0) 253 (49.4) 115 (50.4)
HER2 12.07 12.55 <0.001 16.04 13.16
Negative 371 (78.1) 212 (80.0) 540 (78.5) 43 (82.7) 238 (86.9) 345 (74.0) 421 (79.1) 162 (77.9) 406 (79.3) 177 (34.6)
Positive 104 (21.9) 53 (20.0) 148 (21.5) 9 (17.3) 36 (13.1) 121 (26.0) 111 (20.9) 46 (22.1) 106 (20.7) 51 (22.4)
Tumor stage 0.357 14.00 3.570 0.189 0.189
T1 214 (45.1) 144 (54.3) 331 (48.1) 27 (51.9) 142 (51.8) 216 (46.4) 241 (45.3) 117 (56.2) 231 (45.1) 127 (55.7)
T2/T3 261 (54.9) 121 (45.7) 357 (51.9) 25 (48.1) 132 (48.2) 250 (53.6) 291 (54.7) 91 (43.8) 281 (54.9) 101 (44.3)
Nodal stage 6.531 13.90 3.969 5.901 10.87
N0 273 (57.5) 163 (61.5) 407 (59.2) 29 (55.8) 170 (62.0) 266 (57.1) 320 (60.2) 116 (55.8) 306 (59.8) 130 (57.0)
N1/N2/N3 202 (42.5) 102 (38.5) 281 (40.8) 23 (44.2) 104 (38.0) 200 (42.9) 212 (39.8) 92 (44.2) 206 (40.2) 98 (43.0)
Ki-67 LI (%,
mean ± SD)
18.2 ± 19.8 17.8 ± 18.2 16.10 18.4 ± 19.4 18.9 ± 17.6 15.77 16.0 ± 19.2 19.3 ± 19.2 0567 21.4 ± 20.8 9.5 ± 10.6 <0.001 18.5 ± 19.7 17.0 ± 18.1 7.161
Tumor recurrence 18.81 9.765 18.83 3.339 19.80
Absent 430 (90.5) 241 (90.9) 622 (90.4) 49 (94.2) 248 (90.5) 423 (90.8) 477 (89.7) 194 (93.3) 464 (90.6) 207 (90.8)
Present 45 (9.5) 24 (9.1) 66 (9.6) 3 (5.8) 26 (9.5) 43 (9.2) 55 (10.3) 14 (6.7) 48 (9.4) 21 (9.2)
Death 8.925 12.89 14.53 10.03 14.28
Survival 435 (91.6) 238 (89.8) 624 (90.7) 49 (94.2) 251 (91.6) 422 (90.6) 481 (90.4) 192 (92.3) 467 (91.2) 206 (90.3)
Death 40 (8.4) 27 (10.2) 64 (9.3) 3 (5.8) 23 (8.4) 44 (9.4) 51 (9.6) 16 (7.7) 45 (8.8) 22 (9.7)
aP-values are corrected for multiple testing using the Bonferroni correction. BNIP3, BCL2/adenovirus E1B 19-kDa interacting protein 3; CAIX, carbonic anhydrase IX; Glut-1, glucose transporter 1; LC3A, microtubule-associated
protein 1 light chain 3α; LC3B, microtubule-associated protein 1 light chain 3β; LI, labeling index; MCT4, monocarboxylate transporter 4; TNBC, triple-negative breast cancer.
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Table 6 Clinicopathologic characteristics of patients according to metabolic phenotypea
Parameters Warburg type Reverse Warburg Mixed type Null type P-value
(n = 298) (%) type (n = 54) (%) (n = 62) (%) (n = 326) (%)
Age (years, mean ± SD) 48.5 ± 11.7 52.0 ± 10.2 51.3 ± 10.2 50.1 ± 10.5 0.052
Histologic grade <0.001
I/II 169 (56.7) 41 (75.9) 23 (37.0) 258 (79.1)
III 129 (43.3) 13 (24.1) 39 (72.2) 68 (20.9)
Tumor stage 0.017
T1 123 (41.3) 29 (53.7) 34 (54.8) 172 (52.8)
T2/T3 175 (58.7) 25 (46.3) 28 (45.2) 154 (47.2)
Nodal stage 0.457
N0 177 (59.3) 27 (50.0) 40 (64.5) 192 (58.9)
N1/N2/N3 121 (40.6) 27 (50.0) 22 (35.5) 134 (41.1)
Estrogen receptor status <0.001
Negative 152 (51.0) 15 (27.8) 39 (62.9) 80 (24.5)
Positive 146 (49.0) 39 (72.2) 23 (37.1) 246 (75.5)
Progesterone receptor status <0.001
Negative 181 (60.7) 22 (40.7) 40 (64.5) 129 (39.6)
Positive 117 (39.3) 32 (59.3) 22 (35.5) 197 (60.4)
HER2 status 0.006
Negative 252 (84.6) 36 (66.7) 47 (75.8) 248 (76.1)
Positive 46 (15.4) 18 (33.3) 15 (24.2) 78 (23.9)
Molecular subtype <0.001
Luminal A 91 (30.5) 22 (40.7) 12 (19.4) 173 (53.1)
Luminal B 58 (19.5) 18 (33.3) 13 (21.0) 77 (23.6)
HER2 22 (7.4) 7 (13.0) 10 (16.1) 30 (9.2)
Triple-negative 127 (42.6) 7 (13.0) 27 (43.5) 46 (14.1)
ATP synthase in tumor 0.178
Negative 8 (2.7) 1 (1.9) 2 (3.2) 19 (5.8)
Positive 290 (97.3) 53 (98.1) 60 (96.8) 307 (94.2)
ATP synthase in stroma <0.001
Negative 247 (82.9) 29 (53.7) 33 (53.2) 261 (80.1)
Positive 51 (17.1) 25 (46.3) 29 (46.8) 65 (19.9)
Glutaminase in tumor 0.512
Negative 84 (28.2) 13 (24.1) 17 (27.4) 105 (32.2)
Positive 214 (71.8) 41 (75.9) 45 (72.6) 221 (67.8)
Glutaminase in stroma <0.001
Negative 206 (69.1) 20 (37.0) 29 (46.8) 240 (73.6)
Positive 92 (30.9) 34 (63.0) 33 (53.2) 86 (26.4)
Tumor mitochondrial status 0.217
Dysfunctional 94 (31.5) 20 (37.0) 26 (41.9) 96 (29.4)
Functional 204 (68.5) 34 (63.0) 36 (58.1) 230 (70.6)
Stroma mitochondrial status 0.055
Dysfunctional 13 (4.4) 3 (5.6) 8 (12.9) 16 (4.9)
Functional 285 (95.6) 51 (94.4) 54 (87.1) 310 (95.1)
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Table 6 Clinicopathologic characteristics of patients according to metabolic phenotypea (Continued)
Tumor autophagy status <0.001
Activated 168 (56.4) 28 (51.9) 45 (72.6) 117 (35.9)
Nonactivated 130 (43.6) 26 (48.1) 17 (27.4) 209 (64.1)
Stroma autophagy status <0.001
Activated 9 (3.0) 11 (20.4) 13 (21.0) 21 (6.4)
Nonactivated 289 (97.0) 43 (79.6) 49 (79.0) 305 (93.6)
MCT4 in tumor <0.001
Negative 180 (60.4) 38 (70.4) 40 (64.5) 282 (86.5)
Positive 118 (39.6) 16 (29.6) 22 (35.5) 44 (13.5)
MCT4 in stroma <0.001
Negative 157 (52.7) 22 (40.7) 20 (32.3) 219 (67.2)
Positive 141 (47.3) 32 (59.3) 42 (67.7) 107 (32.8)
Ki-67 LI (%, mean ± SD) 24.6 ± 22.5 13.2 ± 11.1 25.2 ± 18.6 11.5 ± 14.1 <0.001
Tumor recurrence 38 (12.8) 6 (11.1) 4 (6.5) 21 (6.4) 0.043
Patient’s death 36 (12.1) 5 (9.3) 6 (9.7) 20 (6.1) 0.081
aLI, labeling index; MCT4, monocarboxylate transporter 4.
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(OR) = 2.7, 95% CI = 1.7 to 4.5; P < 0.001), N stage (N0 vs.
N1/2/3, OR = 2.3, 95% CI = 1.4 to 3.8; P = 0.001) and T
stage (T1 vs. T2/3, OR = 2.4, 95% CI = 1.3 to 4.4; P = 0.002)
and those associated with shorter OS were ER negativity
(OR = 3.3, 95% CI = 2.0 to 5.5; P < 0.001) and N stage
(N0 vs. N1/2/3, OR = 2.3, 95% CI = 1.4 to 3.8; P = 0.001).
Western blot analysis of metabolism-related proteins in
tumor and stroma according to tumor phenotype
Western blot analysis was performed to investigate ex-
pression of metabolism-related proteins in tumor and
stroma according to the tumor phenotype. The expression
of Glut-1 and ATP synthase was higher in HER2 and
TNBC types, and the expression was higher in tumor than
in stroma (Figure 3). The expression of p62 was higher in
tumor than stroma, regardless of the tumor phenotype.
Discussion
In the present study, we investigated the differential
expression of metabolism-related markers according
to the subtypes of breast cancer. Expression of gly-
colysis markers such as Glut-1, CAIX and MCT-4
was highest in TNBC, which is consistent with the results
of previous studies showing higher expression of Glut-1
and CAIX in basal-like breast cancer [19]. The active meta-
bolic status of a tumor can be inferred from common histo-
logic features of TNBC, such as high-grade nuclei, high-
grade prominent necrosis and increased mitotic activity
[20], and this was supported by the results of IHC in the
present study. Tumor expression of Glut-1 was associ-
ated with higher histologic grade (P < 0.001), ER nega-
tivity (P < 0.001), higher T stage (P < 0.001), and higherKi-67 LI (P < 0.001), whereas CAIX was associated with
higher Ki-67 LI (P < 0.001). Tumor expression of MCT4
was associated with higher histologic grade (P < 0.001), ER
negativity (P < 0.001), PR negativity (P < 0.001), higher T
stage (P < 0.001) and higher Ki-67 LI (P < 0.001). In
addition, expression of Glut-1, CAIX and MCT-4 was asso-
ciated with factors reflecting higher metabolic status. In
contrast, tumor expression of Glut-1, CAIX and MCT-4
was lowest in luminal A and B. Luminal type tumors tend
to show a lower grade, lower mitotic index and less necrosis
than the HER2 type or TNBC, suggesting nonactive meta-
bolic status of the tumor, which was supported by the
results of IHC.
The expression of Glut-1, CAIX, BNIP3, MCT4,
LC3A, LC3B and p62 was observed not only in tumor
cells but also in stromal cells, which has not been thor-
oughly described in previous studies. The reverse Warburg
effect theory suggests that tumor stroma, along with
the tumor per se, plays a role in cancer metabolism
[2-5]. According to this theory, metabolism in stromal
cells occurs through glycolysis due to dysfunctional
mitochondria caused by increased autophagy, whereas
metabolism of tumor cells occurs through OXPHOS in
functional mitochondria. This contrasts with the conven-
tional Warburg effect theory, which states that glycolysis
is the major metabolic process in tumor cells. The major
metabolic phenotypes in this study were the Warburg type
(40.3%) and the null type (44.0%), according to the
metabolic processes of tumor and stromal cells. We
found that each metabolic phenotype investigated had
different characteristics. The mixed type had higher
histologic grade, ER negativity, PR negativity and higher
Ki-67 LI, in contrast to the null type, which had lower
Figure 1 Histologic and immunohistochemical features according to metabolic phenotypes of breast cancer. The Warburg and mixed
types show high histologic grade, estrogen receptor (ER) negativity and high Ki-67 labeling index (LI). In contrast, the reverse Warburg and null
types show low histologic grade, ER positivity and low Ki-67 LI. ATP synthase and glutaminase were high in the reverse Warburg and mixed types
and low in the Warburg and null types (P < 0.001). BNIP3, BCL2/adenovirus E1B 19-kDa interacting protein 3; CAIX, carbonic anhydrase IX; GLUT1,
glucose transporter 1; H & E, hematoxylin and eosin; MCT4, monocarboxylate transporter 4.
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(P < 0.001). As both tumor cells and stromal cells are
glycolytic in the mixed type and nonglycolytic in the null
type, we speculate that the mixed type is a group of
tumors with high metabolic activity and that the null type
consists of tumors with lower metabolic activity. The
results of the present study show that the mixed type had
the highest percentage of activated autophagy, whereas
the null type had the lowest percentage, thus supportingthis hypothesis. In addition, different molecular subtypes of
breast cancer were classified into different metabolic types.
TNBC constituted the highest percentage of Warburg type
and mixed type, whereas the luminal A type constituted the
highest percentage of reverse Warburg type and null type
(P < 0.001). Moreover, the Warburg type and the mixed
type were classified into groups with a higher Ki-67 LI,
whereas the reverse Warburg type and the null type were
classified into groups with a lower Ki-67 LI (P < 0.001).
Table 7 Univariate analysis of the expression of metabolism-related proteins in breast cancers and disease-free
survival or overall survival by logrank testa
Immunohistochemical
factors
Number of patients/
recurrence/death
Disease-free survival Overall survival
Mean survival
(95% CI), months
P-value Mean survival
(95% CI), months
P-value
Glut-1 in tumor 0.010 0.023
Negative 504/37/37 128 (125 to 131) 131 (128 to 134)
Positive 236/32/30 119 (112 to 126) 123 (118 to 128)
Glut-1 in stroma n/a n/a
Negative 724/69/67 n/a n/a
Positive 16/0/0 n/a n/a
CAIX in tumor 0.740 0.222
Negative 520/49/45 126 (122 to 130) 130 (127 to 132)
Positive 220/20/22 108 (102 to 113) 123 (117 to 130)
CAIX in stroma 0.927 0.496
Negative 627/59/56 125 (122 to 129) 129 (126 to 132)
Positive 113/10/11 103 (98 to 108) 116 (109 to 123)
ATP synthase in tumor 0.506 0.936
Negative 30/4/3 102 (90 to 114) 129 (117 to 141)
Positive 710/65/64 125 (122 to 129) 128 (126 to 131)
ATP synthase in stroma 0.783 0.398
Negative 570/53/50 125 (121 to 129) 129 (126 to 132)
Positive 170/16/17 118 (112 to 124) 122 (115 to 128)
Glutaminase in tumor 0.323 0.164
Negative 219/24/25 123 (117 to 128) 126 (120 to 131)
Positive 521/45/42 126 (122 to 130) 130 (127 to 133)
Glutaminase in stroma 0.554 0.596
Negative 495/49/48 123 (119 to 128) 128 (125 to 131)
Positive 245/20/19 127 (121 to 132) 128 (124 to 133)
BNIP3 in tumor 0.004 0.426
Negative 504/59/50 123 (119 to 127) 128 (124 to 131)
Positive 236/10/17 123 (119 to 127) 131 (126 to 135)
BNIP3 in stroma 0.191 0.973
Negative 700/68/64 125 (121 to 128) 128 (126 to 131)
Positive 40/1/3 116 (111 to 121) 121 (112 to 129)
MCT4 in tumor 0.550 0.451
Negative 540/49/47 125 (121 to 129) 129 (126 to 132)
Positive 200/20/20 116 (111 to 121) 126 (120 to 131)
MCT4 in stroma 0.673 0.262
Negative 418/42/44 123 (118 to 127) 127 (123 to 131)
Positive 322/27/23 128 (124 to 132) 130 (126 to 133)
Cytoplasmic beclin-1 0.169 0.566
Negative 406/46/38 124 (119 to 128) 129 (126 to 132)
Positive 334/23/29 121 (118 to 124) 126 (123 to 130)
Nuclear beclin-1 0.157 0.031
Negative 666/66/66 125 (121 to 128) 128 (125 to 131)
Positive 74/3/1 111 (106 to 115) 136 (132 to 139)
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Table 7 Univariate analysis of the expression of metabolism-related proteins in breast cancers and disease-free
survival or overall survival by logrank testa (Continued)
LC3A in tumor 0.085 0.299
Negative 669/59/59 126 (122 to 129) 129 (126 to 132)
Positive 71/10/8 113 (103 to 122) 124 (115 to 133)
LC3A in stroma 0.801 0.541
Negative 687/65/64 125 (122 to 129) 128 (126 to 131)
Positive 53/4/3 65 (62 to 68) 66 (64 to 68)
LC3B in tumor 0.990 0.271
Negative 475/45/40 125 (121 to 130) 130 (127 to 133)
Positive 265/24/27 118 (113 to 123) 125 (120 to 130)
LC3B in stroma 0.481 0.565
Negative 688/66/64 125 (122 to 129) 128 (126 to 131)
Positive 52/3/3 63 (60 to 66) 64 (62 to 66)
Cytoplasmic p62 in tumor 0.958 0.528
Negative 274/26/23 121 (112 to 129) 129 (125 to 133)
Positive 466/43/44 126 (122 to 130) 128 (125 to 131)
Nuclear p62 in tumor 0.210 0.646
Negative 532/55/51 125 (122 to 129) 128 (125 to 131)
Positive 208/14/16 117 (110 to 124) 128 (122 to 133)
Nuclear p62 in stroma 0.720 0.387
Negative 512/48/45 126 (122 to 130) 129 (126 to 132)
Positive 228/21/22 104 (99 to 109) 124 (118 to 130)
Tumor phenotype <0.001 <0.001
Luminal A 298/15/14 130 (126 to 133) 134 (131 to 137)
Luminal B 166/12/11 129 (124 to 134) 130 (124 to 135)
HER2 69/11/12 111 (100 to 121) 119 (108 to 130)
TNBC 207/31/30 116 (109 to 124) 120 (114 to 126)
Metabolic status 0.037 0.045
Warburg type 298/38/36 119 (112 to 126) 124 (119 to 128)
Reverse Warburg type 54/6/5 90 (83 to 96) 113 (106 to 121)
Mixed type 62/4/6 105 (100 to 111) 112 (99 to 126)
Null type 326/21/20 129 (126 to 133) 132 (129 to 136)
aBNIP3, BCL2/adenovirus E1B 19-kDa interacting protein 3; CAIX, carbonic anhydrase IX; Glut-1, glucose transporter 1; LC3A, microtubule-associated protein 1 light
chain 3α; LC3B, microtubule-associated protein 1 light chain 3β; MCT4, monocarboxylate transporter 4; n/a, not applicable; TNBC, triple-negative breast cancer.
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the reverse Warburg effect in which a luminal A breast
cancer cell line, MCF-7, was used for in vitro study [6].
Thus, further in vitro studies should be carried out with
various cell lines showing different molecular subtypes.
We identified the expression of a mitochondrial
metabolism-related protein such as ATP synthase and
glutaminase in the tumor and stroma in the present
study. Notably, stromal expression of ATP synthase
and glutaminase was high in the reverse Warburg type
and mixed type and low in the Warburg type and null type
(P < 0.001). We speculate that stroma showing glycolysishave high mitochondrial metabolic activity, as both the
reverse Warburg and mixed types are subtypes of the
glycolysis type of stroma by definition. Because it has
also been reported that certain types of tumor generate
ATP through glycolysis as well as through mitochondrial
OXPHOS, the hypothesis that dual types of stromal me-
tabolism via the glycolysis pathway and the mitochondrial
pathway should be investigated further.
The present study shows that the Warburg type and
mixed type consisted of metabolically active and biologic-
ally aggressive tumors, whereas the reverse Warburg
type and null type consisted of metabolically inactive
Figure 3 Expression of metabolism-related proteins in tumor
and stroma assessed by Western blot analysis according to
tumor phenotype. CAIX, carbonic anhydrase IX; GLS1, glutaminase
1; Glut-1, glucose transporter 1; LMA, luminal A; LMB, luminal B;
LC3A, microtubule-associated protein 1 light chain 3α; MCT4,
monocarboxylate transporter 4; S, stroma; T, tumor; TNBC,
triple-negative breast cancer.
Figure 2 Disease-free survival (a) and overall survival curves (b) according to the metabolic phenotypes of breast cancer.
Choi et al. Breast Cancer Research 2013, 15:R78 Page 18 of 20
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suggests that glycolysis of tumors significantly affects
their metabolic and biological characteristics. The asso-
ciation of Glut-1 with shorter DFS and OS in univariate
analysis supports this hypothesis.
A potential limitation of this study is the use of TMA
cores for analysis, which may not truly represent the whole
tumor. Although it is a reasonable contention, given the
well-known intrinsic heterogeneity of breast cancer, this
limitation was overcome by using two 3-mm tissue cores
because it was previously reported that TMA with two
0.6-mm cores were representative of standard full tissue
sections in breast cancer [21].
Among the breast cancer subtypes, TNBC comprised
28% of the total cases in this study, which is higher than
the previously reported 12% to 24%. This difference can
be attributed to possible differences in ethnic incidence,
as reported previously, and to the overestimation of the
true incidence potentially by the use of TMA containing
part of the tumor, as we defined TNBC as all negative for
ER, PR and HER2, which is similar to known phenomena
of the discordance of ER, PR and HER2 expression between
samples from core biopsy and excision [22-24]. Last,
erroneous results of ER, PR and HER2 expression may
affect the incidence, given that a 10% of false-negative rate
and a 5% of false-positive rate were reported in ER expres-
sion, whereas a 4% of false-negative and false-positive cases
were reported in HER2 [25]. Thus, cautious interpretation
of the expression of those markers seems crucial, as misin-
terpretation of results may lead to the misclassification of
the molecular subtypes.
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Breast cancer is heterogeneous in its metabolic status,
and therefore it can be classified into various metabolic
phenotypes. Specifically, the Warburg and mixed types
had strong associations with TNBC, whereas the reverse
Warburg type and the null type were associated with the
luminal type, suggesting a correlation between metabolic
phenotype and the biology of breast cancer.
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